Glial Fibrillary Acidic Protein (GFAP) is one of the most abundant proteins of the nervous system and is concentrated in astrocytic cells, though it is also found in neural stem cells, Bergman glia, Mueller cells and non myelinating Schwann cells. On CNS damage GFAP may be released in cerebrospinal fluid (CSF) or blood, and the detection of this protein may provide useful information about the type and degree of damage. As with pNF-H the basic finding that low levels of GFAP in CSF or blood predict a better patient or experimental animal outcome than higher levels. An exciting finding is that blood levels of GFAP appear to allow the discrimination between ischemic and hemorrhagic stroke shortly after stroke has occurred. This finding, if confirmed, has profound clinical significance as the treatment of each kind of stroke is different, and there is no other current means of discriminating these two types of stroke.

We have been supplying GFAP antibodies to the research community for many years, and so were well positioned to develop ELISA type assays to this protein. Our current assay uses the mouse monoclonal antibody MCA-2A5 in the capture role and an affinity purified version of our rabbit GFAP polyclonal antibody RPCA-GFAP in detection. We can run GFAP assays on a fee for service basis. For details of our GFAP assays email


Foerch, C. et al. Diagnostic accuracy of plasma glial fibrillary acidic protein for differentiating intracerebral hemorrhage and cerebral ischemia in patients with symptoms of acute stroke. Clin Chem. 58:237-45 (2011).